Why Gilead Sciences (GILD) Stock Is Up Today [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
as the company announced a series of positive developments, including successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government. Gilead reported that its investigational single-tablet regimen for HIV, which combined bictegravir and lenacapavir, met its primary goal in a phase III study, boosting its chances for future approval. Adding to the good news, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved lenacapavir for preventing sexually transmitted HIV-1 infection, marking the introduction of a long-acting, six-month preventative option. Furthermore, Gilead reached a three-year agreement with the U.S. government to offer discounted pricing on existing and future medicines, including treatments for HIV, Hepatitis, and COVID-19. After the initial pop the shares cooled down to $124.46, up 2.5% from previous close. Is now the time to buy Gilead S
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans [Yahoo! Finance]Yahoo! Finance
- Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for AmericansBusiness Wire
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & ComplianceBusiness Wire
- Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website